Regenerative therapies in electrophysiology and pacing: Introducing the next steps

Journal of Interventional Cardiac Electrophysiology

Volumn 31, Issue 1, 2011, Pages 3-16

  Boink, Gerard J J ^a,b,c   Rosen, Michael R ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Arrhythmias; Cell therapy; Gene therapy

Indexed keywords

VIRUS VECTOR;

BRADYCARDIA; CELL THERAPY; CONGESTIVE HEART FAILURE; ELECTROPHYSIOLOGY; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE THERAPY; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART INFARCTION; HEART PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; TACHYCARDIA; TISSUE TRANSPLANTATION;

ARRHYTHMIAS, CARDIAC; BRADYCARDIA; CARDIAC ELECTROPHYSIOLOGY; CARDIAC PACING, ARTIFICIAL; GENE THERAPY; HUMANS; TACHYCARDIA; TISSUE THERAPY;

EID: 79959566380     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-010-9529-x     Document Type: Review

References (115)

1. Greener, I., Donahue, J.K. (2010). Gene therapy strategies for cardiac electrical dysfunction. Journal of Molecular and Cellular Cardiology (in press).
2. Rosen, M. R., Danilo, P., Jr., & Robinson, R. B. (2009). Gene and cell therapy for life-threatening cardiac arrhythmias. Dialogues in Cardiovascular Medicine, 14(1), 44-51.
3. Cho, H. C., & Marbán, E. (2010). Biological therapies for cardiac arrhythmias: Can genes and cells replace drugs and devices? Circulation Research, 106(4), 674-685.
4. Dimmeler, S., & Zeiher, A. M. (2009). Cell therapy of acute myocardial infarction: Open questions. Cardiology, 113(3), 155-160.
5. Gupta, R., & Losordo, D. W. (2010). Challenges in the translation of cardiovascular cell therapy. Journal of Nuclear Medicine, 51(Suppl 1), 122S-127S.
6. Wollert, K. C., & Drexler, H. (2010). Cell therapy for the treatment of coronary heart disease: A critical appraisal. Nature Reviews Cardiology, 7(4), 204-215.
7. Abdel-Latif, A., Bolli, R., Tleyjeh, I. M., Montori, V. M., Perin, E. C., Hornung, C. A., et al. (2007). Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Archives of Internal Medicine, 167(10), 989-997.
8. Hare, J. M., Traverse, J. H., Henry, T. D., Dib, N., Strumpf, R. K., Schulman, S. P., et al. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology, 54(24), 2277-2286.
9. Hatzistergos, K.E., Quevedo, H., Oskouei, B.N., Hu, Q., Feigenbaum, G.S., Margitich, I.S., et al. (2010). Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circulation Research (in press)
10. Kupatt, C., Hinkel, R., Lamparter, M., von Bruhl, M. L., Pohl, T., Horstkotte, J., et al. (2005). Retroinfusion of embryonic endothelial progenitor cells attenuates ischemia-reperfusion injury in pigs: Role of phosphatidylinositol 3-kinase/AKT kinase. Circulation, 112(9 Suppl), I117-I122. (Pubitemid 41266662)
11. Gnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., et al. (2005). Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nature Medicine, 11(4), 367-368. (Pubitemid 40562318)
12. Uemura, R., Xu, M., Ahmad, N., & Ashraf, M. (2006). Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circulation Research, 98(11), 1414-1421. (Pubitemid 43948066)
13. Mirotsou, M., Jayawardena, T. M., Schmeckpeper, J., Gnecchi, M., Dzau, V.J. (2010). Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. Journal of Molecular and Cellular Cardiology (in press).
14. Hinkel, R., El-Aouni, C., Olson, T., Horstkotte, J., Mayer, S., Muller, S., et al. (2008). Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation, 117(17), 2232-2240.
15. Morishita, Y., Poirier, R. A., & Rohner, R. F. (1981). Sinoatrial node transplantation in the dog. Vascular and Endovascular Surgery, 15, 388-393.
16. Edelberg, J. M., Aird, W. C., & Rosenberg, R. D. (1998). Enhancement of murine cardiac chronotropy by the molecular transfer of the human β2-adrenergic receptor cDNA. The Journal of Clinical Investigation, 101(2), 337-343. (Pubitemid 28067330)
17. Edelberg, J. M., Huang, D. T., Josephson, M. E., & Rosenberg, R. D. (2001). Molecular enhancement of porcine cardiac chronotropy. Heart, 86(5), 559-562. (Pubitemid 32999871)
18. Ruhparwar, A., Tebbenjohanns, J., Niehaus, M., Mengel, M., Irtel, T., Kofidis, T., et al. (2002). Transplanted fetal cardiomyocytes as cardiac pacemaker. European Journal of Cardiothoracic Surgery, 21(5), 853-857. (Pubitemid 34308944)
19. Miake, J.,Marbán, E., & Nuss, H. B. (2002). Biological pacemaker created by gene transfer. Nature, 419(6903), 132-133.
20. Boink, G. J. J., Verkerk, A. O., van Amersfoorth, S. C., Tasseron, S. J., van der, R. R., Bakker, D., et al. (2008). Engineering physiologically controlled pacemaker cells with lentiviral HCN4 gene transfer. Journal of Gene Medicine, 10 (5), 487-497. (Pubitemid 351753518)
21. Qu, J., Plotnikov, A. N., Danilo, P., Jr., Shlapakova, I., Cohen, I. S., Robinson, R. B., et al. (2003). Expression and function of a biological pacemaker in canine heart. Circulation, 107(8), 1106-1109. (Pubitemid 36297200)
22. Tse, H. F., Xue, T., Lau, C. P., Siu, C. W., Wang, K., Zhang, Q. Y., et al. (2006). Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation, 114(10), 1000-1011. (Pubitemid 44358876)
23. Plotnikov, A. N., Sosunov, E. A., Qu, J., Shlapakova, I. N., Anyukhovsky, E. P., Liu, L., et al. (2004). Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation, 109(4), 506-512. (Pubitemid 38168514)
24. Bucchi, A., Plotnikov, A. N., Shlapakova, I., Danilo, P., Jr., Kryukova, Y., Qu, J., et al. (2006). Wild-type and mutant HCN channels in a tandem biological-electronic cardiac pacemaker. Circulation, 114(10), 992-999. (Pubitemid 44358875)
25. Plotnikov, A. N., Bucchi, A., Shlapakova, I., Danilo, P., Jr., Brink, P. R., Robinson, R. B., et al. (2008). HCN212-channel biological pacemakers manifesting ventricular tachyarrhythmias are responsive to treatment with I(f) blockade. Heart Rhythm, 5 (2), 282-288.
26. Kashiwakura, Y., Cho, H. C., Barth, A. S., Azene, E., & Marbán, E. (2006). Gene transfer of a synthetic pacemaker channel into the heart: A novel strategy for biological pacing. Circulation, 114(16), 1682-1686.
27. Kehat, I., Khimovich, L., Caspi, O., Gepstein, A., Shofti, R., Arbel, G., et al. (2004). Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nature Biotechnology, 22(10), 1282-1289. (Pubitemid 39341201)
28. Xue, T., Cho, H. C., Akar, F. G., Tsang, S. Y., Jones, S. P., Marbán, E., et al. (2005). Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: Insights into the development of cell-based pacemakers. Circulation, 111(1), 11-20. (Pubitemid 40070838)
29. Potapova, I., Plotnikov, A., Lu, Z., Danilo, P., Jr., Valiunas, V., Qu, J., et al. (2004). Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circulation Research, 94(7), 952-959. (Pubitemid 38490073)
30. Rosen, M. R. (2006). Are stem cells drugs? The regulation of stem cell research and development. Circulation, 114(18), 1992-2000.
31. Zimmet, J. M., & Hare, J. M. (2005). Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. Basic Research in Cardiology, 100(6), 471-481. (Pubitemid 41662427)
32. Plotnikov, A. N., Shlapakova, I., Szabolcs, M. J., Danilo, P., Jr., Lorell, B. H., Potapova, I. A., et al. (2007). Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart. Circulation, 116 (7), 706-713. (Pubitemid 47255987)
33. Valiunas, V., Kanaporis, G., Valiuniene, L., Gordon, C., Wang, H. Z., Li, L., et al. (2009). Coupling an HCN2-expressing cell to a myocyte creates a two-cell pacing unit. The Journal of Physiology, 587(Pt 21), 5211-5226.
34. Cho, H. C., Kashiwakura, Y., & Marbán, E. (2007). Creation of a biological pacemaker by cell fusion. Circulation Research, 100 (8), 1112-1115. (Pubitemid 46684124)
35. Zhang, J., Wilson, G. F., Soerens, A. G., Koonce, C. H., Yu, J., Palecek, S. P., et al. (2009). Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research, 104(4), e30-e41.
36. Novak, A., Shtrichman, R., Germanguz, I., Segev, H., Zeevi-Levin, N., Fishman, B., et al. (2010). Enhanced reprogramming and cardiac differentiation of human keratinocytes derived from plucked hair follicle, using single excisable lentivirus. Cellular Reprogramming, (in press).
37. Choi, Y. H., Stamm, C., Hammer, P. E., Kwaku, K. F., Marler, J. J., Friehs, I., et al. (2006). Cardiac conduction through engineered tissue. The American Journal of Pathology, 169(1), 72-85.
38. McSpadden, L. C., Kirkton, R. D., & Bursac, N. (2009). Cell therapies for arrhythmias: Genetically engineered coupling determines the effect on anisotropic cardiac conduction. Circulation, 120(20), S765-S766.
39. Yokokawa, M., Ohnishi, S., Ishibashi-Ueda, H., Obata, H., Otani, K., Miyahara, Y., et al. (2008). Transplantation of mesenchymal stem cells improves atrioventricular conduction in a rat model of complete atrioventricular block. Cell Transplantation, 17(10-11), 1145-1155.
40. Members of the Sicilian Gambit. (2001). New approaches to antiarrhythmic therapy, Part I: Emerging therapeutic applications of the cell biology of cardiac arrhythmias. Circulation, 104(23), 2865-2873.
41. Aliot, E. M., Stevenson, W. G., Almendral-Garrote, J. M., Bogun, F., Calkins, C. H., Delacretaz, E., et al. (2009). EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: Developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm, 6(6), 886-933.
42. Camm, A.J., Kirchhof, P., Lip, G.Y., Schotten, U., Savelieva, I., Ernst, S., et al. (2010). Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, Epublished ahead of print.
43. Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Journal of the American College of Cardiology, 48(4), 854-906. (Pubitemid 44175743)
44. Hohnloser, S. H., Kuck, K. H., Dorian, P., Roberts, R. S., Hampton, J. R., Hatala, R., et al. (2004). Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. The New England Journal of Medicine, 351(24), 2481-2488. (Pubitemid 39603155)
45. Raviele, A., Bongiorni, M. G., Brignole, M., Cappato, R., Capucci, A., Gaita, F., et al. (2005). Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BEta blocker STrategy plus ICD trial. Europace, 7(4), 327-337.
46. Bunch, T. J., Mahapatra, S., Bruce, G. K., Johnson, S. B., Miller, D. V., Horne, B. D., et al. (2006). Impact of transforming growth factor-β1 on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. Circulation, 113(21), 2485-2494. (Pubitemid 43948026)
47. Bauer, A., McDonald, A. D., Nasir, K., Peller, L., Rade, J. J., Miller, J. M., et al. (2004). Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation, 110(19), 3115-3120. (Pubitemid 39492007)
48. Donahue, J. K., Heldman, A. W., Fraser, H., McDonald, A. D., Miller, J. M., Rade, J. J., et al. (2000). Focal modification of electrical conduction in the heart by viral gene transfer. Nature Medicine, 6(12), 1395-1398. (Pubitemid 32001025)
49. Murata, M., Cingolani, E., McDonald, A. D., Donahue, J. K., & Marbán, E. (2004). Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circulation Research, 95(4), 398-405. (Pubitemid 39100458)
50. Burton, D. Y., Song, C., Fishbein, I., Hazelwood, S., Li, Q., Defelice, S., et al. (2003). The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: In vitro and in vivo feasibility studies. Human Gene Therapy, 14(9), 907-922. (Pubitemid 36693799)
51. Kikuchi, K., McDonald, A. D., Sasano, T., & Donahue, J. K. (2005). Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation, 111(3), 264-270. (Pubitemid 40165331)
52. Amit, G., Kikuchi, K., Greener, I. D., Yang, L., Novack, V., & Donahue, J. K. (2010). Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation, 121(21), 2263-2270.
53. Bikou, O., Trappe, K., Koch, M., Becker, R., Kelemen, K., Menrath, B., et al. (2009). Genetic ablation of atrial fibrillation in pigs with atrial fibrillation. Circulation, 120: S593 (abstract).
54. Stevenson, W. G., Wilber, D. J., Natale, A., Jackman, W. M., Marchlinski, F. E., Talbert, T., et al. (2008). Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: The multicenter thermocool ventricular tachycardia ablation trial. Circulation, 118(25), 2773-2782.
55. Sasano, T., McDonald, A. D., Kikuchi, K., & Donahue, J. K. (2006). Molecular ablation of ventricular tachycardia after myocardial infarction. Nature Medicine, 12(11), 1256-1258. (Pubitemid 44706927)
56. Trimmer, J. S., Cooperman, S. S., Tomiko, S. A., Zhou, J. Y., Crean, S. M., Boyle, M. B., et al. (1989). Primary structure and functional expression of a mammalian skeletal muscle sodium channel. Neuron, 3(1), 33-49.
57. Hayward, L. J., Brown, R. H., Jr., & Cannon, S. C. (1996). Inactivation defects caused by myotonia-associated mutations in the sodium channel III-IV linker. Journal of Gene Physiology, 107(5), 559-576. (Pubitemid 26140797)
58. Ursell, P. C., Gardner, P. I., Albala, A., Fenoglio, J. J., Jr., & Wit, A. L. (1985). Structural and electrophysiological changes in the epicardial border zone of canine myocardial infarcts during infarct healing. Circulation Research, 56(3), 436-451. (Pubitemid 15119520)
59. Lau, D. H., Clausen, C., Sosunov, E. A., Shlapakova, I. N., Anyukhovsky, E. P., Danilo, P., Jr., et al. (2009). Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: An in silico, in vivo, in vitro study. Circulation, 119(1), 19-27.
60. Coronel, R., Lau, D. H., Sosunov, E. A., Janse, M. J., Danilo, P., Jr., Anyukhovsky, E. P., et al. (2010). Cardiac expression of skeletal muscle sodium channels increases longitudinal conduction velocity in the canine 1-week myocardial infarction. Heart Rhythm, 7(8), 1104-1110.
61. Hennan, J. K., Swillo, R. E., Morgan, G. A., Keith, J. C., Jr., Schaub, R. G., Smith, R. P., et al. (2006). Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. The Journal of Pharmacology and Experimental Therapeutics, 317(1), 236-243.
62. Kjolbye, A. L., Dikshteyn, M., Eloff, B. C., Deschenes, I., & Rosenbaum, D. S. (2008). Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans. American Journal of Physiology. Heart and Circulatory Physiology, 294(1), H41-H49.
63. Dhein, S., Larsen, B. D., Petersen, J. S., & Mohr, F. W. (2003). Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern. Cell Communication & Adhesion, 10(4-6), 371-378. (Pubitemid 38081400)
64. Wiegerinck, R. F., de Bakker, J. M., Opthof, T., de Jonge, N., Kirkels, H., Wilms-Schopman, F. J., et al. (2009). The effect of enhanced gap junctional conductance on ventricular conduction in explanted hearts from patients with heart failure. Basic Research in Cardiology, 104(3), 321-332.
65. Axelsen, L. N., Stahlhut, M., Mohammed, S., Larsen, B. D., Nielsen, M. S., Holstein-Rathlou, N. H., et al. (2006). Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). Journal of Molecular and Cellular Cardiology, 40(6), 790-798. (Pubitemid 43817040)
66. Kitamura, H., Ohnishi, Y., Yoshida, A., Okajima, K., Azumi, H., Ishida, A., et al. (2002). Heterogeneous loss of connexin43 protein in nonischemic dilated cardiomyopathy with ventricular tachycardia. Journal of Cardiovascular Electrophysiology, 13(9), 865-870.
67. Kostin, S., Dammer, S., Hein, S., Klovekorn, W. P., Bauer, E. P., & Schaper, J. (2004). Connexin 43 expression and distribution in compensated and decompensated cardiac hypertrophy in patients with aortic stenosis. Cardiovascular Research, 62(2), 426-436. (Pubitemid 38496555)
68. Sepp, R., Severs, N. J., & Gourdie, R. G. (1996). Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. Heart, 76(5), 412-417. (Pubitemid 26390797)
69. Smith, J. H., Green, C. R., Peters, N. S., Rothery, S., & Severs, N. J. (1991). Altered patterns of gap junction distribution in ischemic heart disease. immunohistochemical study human myocardium using laser scanning confocal microscopy. The American Journal of Pathology, 139(4), 801-821.
70. Peters, N. S., Green, C. R., Poole-Wilson, P. A., & Severs, N. J. (1993). Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation, 88(3), 864-875. (Pubitemid 23264001)
71. Dupont, E., Matsushita, T., Kaba, R. A., Vozzi, C., Coppen, S. R., Khan, N., et al. (2001). Altered connexin expression in human congestive heart failure. Journal of Molecular and Cellular Cardiology, 33(2), 359-371. (Pubitemid 32537933)
72. Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., et al. (2007). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nature Medicine, 13(4), 486-491. (Pubitemid 46559834)
73. Anyukhovsky, E.P., Sosunov, E.A., Kryukova, Y., Prestia, K., Ozgen, N., Cohen, I.S., et al. (2010). Expression of skeletal muscle sodium channel (Nav1.4) or Connexin32 prevents reperfusion arrhythmias in murine heart. Cardiovascular Research, Epublished ahead of print.
74. Kanno, S., Kovacs, A., Yamada, K. A., & Saffitz, J. E. (2003). Connexin43 as a determinant of myocardial infarct size following coronary occlusion in mice. Journal of the American College of Cardiology, 41(4), 681-686. (Pubitemid 36223337)
75. Hawat, G., Benderdour, M., Rousseau, G., & Baroudi, G. (2010). Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury. Pflügers Archives - European The Journal of Physiology, 460 (3), 583-592.
76. Schlack, W., Uebing, A., Schafer, M., Bier, F., Schafer, S., Piper, H. M., et al. (1994). Regional contractile blockade at the onset of reperfusion reduces infarct size in the dog heart. Pflügers Archives - European The Journal of Physiology, 428 (2), 134-141. (Pubitemid 24238857)
77. Garcia-Dorado, D., Inserte, J., Ruiz-Meana, M., Gonzalez, M. A., Solares, J., Julia, M., et al. (1997). Gap junction uncoupler heptanol prevents cell-to-cell progression of hypercontracture and limits necrosis during myocardial reperfusion. Circulation, 96(10), 3579-3586. (Pubitemid 27513436)
78. Schlack, W., Preckel, B., Barthel, H., Obal, D., & Thamer, V. (1997). Halothane reduces reperfusion injury after regional ischaemia in the rabbit heart in vivo. British Journal of Anesthesia, 79(1), 88-96. (Pubitemid 27326766)
79. Lee, T. M., & Chou, T. F. (2003). Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. American Journal of Physiology. Heart and Circulatory Physiology, 285(4), H1650-H1659.
80. Prestia, K., Kelly, C. W., Sosunov, E. A., Anyukhovsky, E. P., Brink, P. R., Rosen, M. R., et al. (2009). Connexin 32 influences infarct size following left anterior descending artery ligation in mice. Heart Rhythm, 6(5 S):S458 (Abstract).
81. Macia, E., & Boyden, P. A. (2009). Stem cell therapy is proarrhythmic. Circulation, 119(13), 1814-1823.
82. Roell, W., Lewalter, T., Sasse, P., Tallini, Y. N., Choi, B. R., Breitbach, M., et al. (2007). Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature, 450 (7171), 819-824. (Pubitemid 350237591)
83. Fernandes, S., van Rijen, H. V., Forest, V., Evain, S., Leblond, A. L., Merot, J., et al. (2009). Cardiac cell therapy: Overexpression of connexin43 in skeletal myoblasts and prevention of ventricular arrhythmias. Journal of Cellular and Molecular Medicine, 13(9B), 3703-3712.
84. Akar, F. G., Wu, R. C., Juang, G. J., Tian, Y., Burysek, M., Disilvestre, D., et al. (2005). Molecular mechanisms underlying K+current downregulation in canine tachycardia-induced heart failure. American Journal of Physiology. Heart and Circulatory Physiology, 288(6), H2887-H2896. (Pubitemid 40720671)
85. Miake, J., Marbán, E., & Nuss, H. B. (2003). Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression. The Journal of Clinical Investigation, 111(10), 1529-1536. (Pubitemid 38063285)
86. de Boer, T. P., van Veen, T. A. B., Houtman, M. J., Jansen, J. A., van Amersfoorth, S. C. M., Doevendans, P. A., et al. (2006). Inhibition of cardiomyocyte automaticity by electrotonic application of inward rectifier current from Kir2.1 expressing cells. Medical and Biological Engineering and Computing, 44(7), 537-542. (Pubitemid 44184465)
87. Mazhari, R., Nuss, H. B., Armoundas, A. A., Winslow, R. L., & Marbán, E. (2002). Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval. The Journal of Clinical Investigation, 109(8), 1083-1090. (Pubitemid 34408583)
88. Brunner, M., Kodirov, S. A., Mitchell, G. F., Buckett, P. D., Shibata, K., Folco, E. J., et al. (2003). In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. American Journal of Physiology. Heart and Circulatory Physiology, 285(1), H194-H203.
89. Kodirov, S. A., Brunner, M., Busconi, L., & Koren, G. (2003). Long-term restitution of 4-aminopyridine-sensitive currents in Kv1DN ventricular myocytes using adeno-associated virus-mediated delivery of Kv1.5. FEBS Letters, 550(1-3), 74-78. (Pubitemid 37281360)
90. Yankelson, L., Feld, Y., Bressler-Stramer, T., Itzhaki, I., Huber, I., Gepstein, A., et al. (2008). Cell therapy for modification of the myocardial electrophysiological substrate. Circulation, 117 (6), 720-731. (Pubitemid 351640673)
91. Nuss, H. B., Johns, D. C., Kaab, S., Tomaselli, G. F., Kass, D., Lawrence, J. H., et al. (1996). Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: A prototype for gene therapy for disorders of cardiac excitability and contractility. Gene Therapy, 3(10), 900-912. (Pubitemid 26348344)
92. Feld, Y., Melamed-Frank, M., Kehat, I., Tal, D., Marom, S., & Gepstein, L. (2002). Electrophysiological modulation of cardiomyocytic tissue by transfected fibroblasts expressing potassium channels: A novel strategy to manipulate excitability. Circulation, 105(4), 522-529. (Pubitemid 34141712)
93. Ennis, I. L., Li, R. A., Murphy, A. M., Marbán, E., & Nuss, H. B. (2002). Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility. The Journal of Clinical Investigation, 109(3), 393-400. (Pubitemid 34141813)
94. Byrne, M. J., Power, J. M., Preovolos, A., Mariani, J. A., Hajjar, R. J., & Kaye, D. M. (2008). Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Therapy, 15 (23), 1550-1557.
95. Hajjar, R. J., Schmidt, U., Matsui, T., Guerrero, J. L., Lee, K. H., Gwathmey, J. K., et al. (1998). Modulation of ventricular function through gene transfer in vivo. Proceedings of the National Academy of Sciences of the United States of America, 95(9), 5251-5256. (Pubitemid 28208584)
96. 2+)-ATPase in a rat model of heart failure. Circulation, 104 (12), 1424-1429.
97. Jaski, B. E., Jessup, M. L., Mancini, D. M., Cappola, T. P., Pauly, D. F., Greenberg, B., et al. (2009). Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. Journal of Cardiac Failure, 15(3), 171-181.
98. Del, M. F., Lebeche, D., Guerrero, J. L., Tsuji, T., Doye, A. A., Gwathmey, J. K., et al. (2004). Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proceedings of the National Academy of Sciences of the United States of America, 101(15), 5622-5627. (Pubitemid 38481206)
99. 2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation, 118(6), 614-624.
100. 2+-ATPase delays myocardial failure after myocardial infarction in rats at a cost of increased acute arrhythmias. Circulation, 109(15), 1898-1903.
101. Cutler, M. J., Wan, X., Laurita, K. R., Hajjar, R. J., & Rosenbaum, D. S. (2009). Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circulation Arrhythmia and Electrophysiology, 2(6), 686-694.
102. Muruve, D. A. (2004). The innate immune response to adenovirus vectors. Human Gene Therapy, 15(12), 1157-1166.
103. Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Molecular Therapy, 16 (6), 1073-1080. (Pubitemid 351737072)
104. Zincarelli, C., Soltys, S., Rengo, G., Koch, W. J., & Rabinowitz, J. E. (2010). Comparative cardiac gene delivery of adenoassociated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clinical and Translational Science, 3(3), 81-89.
105. Boink, G. J. J., Seppen, J., de Bakker, J. M. T., & Tan, H. L. (2006). Gene therapy to create biological pacemakers. Medical & Biological Engineering & Computing, 45, 167-176.
106. Gray, S. J., & Samulski, R. J. (2008). Optimizing gene delivery vectors for the treatment of heart disease. Expert Opinion on Biological Therapy, 8(7), 911-922. (Pubitemid 352007003)
107. Martin-Puig, S., Wang, Z., & Chien, K. R. (2008). Lives of a heart cell: Tracing the origins of cardiac progenitors. Cell Stem Cell, 2(4), 320-331. (Pubitemid 351455247)
108. Freund, C., & Mummery, C. L. (2009). Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as diseasemodels. Journal of Cellular Biochemistry, 107(4), 592-599.
109. Kraitchman, D. L., Heldman, A. W., Atalar, E., Amado, L. C., Martin, B. J., Pittenger, M. F., et al. (2003). In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation, 107(18), 2290-2293.
110. Dick, A. J., Guttman, M. A., Raman, V. K., Peters, D. C., Pessanha, B. S., Hill, J. M., et al. (2003). Magnetic resonance fluoroscopy allows targeted delivery of mesenchymal stem cells to infarct borders in swine. Circulation, 108(23), 2899-2904. (Pubitemid 37517818)
111. Kraitchman, D. L., Tatsumi, M., Gilson, W. D., Ishimori, T., Kedziorek, D., Walczak, P., et al. (2005). Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation, 112(10), 1451-1461. (Pubitemid 41291771)
112. Barbash, I. M., Chouraqui, P., Baron, J., Feinberg, M. S., Etzion, S., Tessone, A., et al. (2003). Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and body distribution. Circulation, 108(7), 863-868. (Pubitemid 37022130)
113. Hofmann, M., Wollert, K. C., Meyer, G. P., Menke, A., Arseniev, L., Hertenstein, B., et al. (2005). Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation, 111 (17), 2198-2202. (Pubitemid 40632435)
114. Rosen, A. B., Kelly, D. J., Schuldt, A. J., Lu, J., Potapova, I. A., Doronin, S. V., et al. (2007). Finding fluorescent needles in the cardiac haystack: Tracking humanmesenchymal stem cells labeled with quantum dots for quantitative in vivo 3-D fluorescence analysis. Stem Cells, 28(8), 2128-2138. (Pubitemid 47258192)
115. Kajstura, J., Rota, M., Whang, B., Cascapera, S., Hosoda, T., Bearzi, C., et al. (2005). Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circulation Research, 96(1), 127-137. (Pubitemid 40095762)